Feb 29 |
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference
|
Feb 21 |
H.C. Wainwright cuts Prelude Therapeutics to neutral, cites valuation
|
Feb 17 |
Here's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation
|
Feb 16 |
Prelude Therapeutics files to sell 7.94M shares for holders
|
Feb 16 |
Prelude Therapeutics GAAP EPS of -$2.02 in-line
|
Feb 15 |
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024
|
Feb 5 |
Prelude Therapeutics: Interesting Pipeline That Is Too Early To Warrant My Buy
|
Feb 3 |
Prelude Therapeutics: Scientifically Interesting Oncology Company With Preclinical Data
|
Jan 14 |
Prelude Therapeutics Incorporated (NASDAQ:PRLD) is definitely on the radar of hedge funds investors who own 33% of the company
|